✦ LIBER ✦

Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogeneous leukaemia

✍ Scribed by W. G. Peters; R. Willemze; L. P. Colly

Book ID: 114790922
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 423 KB
Volume: 40
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.1988.tb00824.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TREATMENT OF REFRACTORY ACUTE LEUKAEMIA

TREATMENT OF REFRACTORY ACUTE LEUKAEMIA WITH HIGH DOSE CYTOSINE ARABINOSIDE

✍ R. Willemze; F. E. Zwaan; J. J. Keuning; G. Colpin 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Treatment of relapsed and refractory acu

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

✍ Martin Gore; Ray Powles; Anil Lakhani; Sarah Milan; Jennifer Maitland; Glen Goss 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 425 KB

A total of 65 patients under the age of 55 with acute leukaemia received high-dose cytosine arabinoside (Ara-C) in combination with high-dose etoposide without an anthracycline. Complete remission rates for patients with relapsed or refractory acute myelogenous leukaemia (AML) were 15/25 (60%) and 1

Remission of rheumatoid arthritis with t

Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA

✍ Ronenn Roubenoff; Richard J. Jones; Judith E. Karp; Mary Betty Stevens 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB 👁 1 views

Treatment of “poor risk” acute nonlympho

Treatment of “poor risk” acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside

✍ Dr. Edward P. Balaban; John V. Cox; Nancy R. Schneider; Cheryl A. Harth; Barbara 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

Treatment of acute nonlymphocytic leukem

Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside

✍ Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 1 views

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours

Intermediate and high-dose ARA-C and m-A

Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma

✍ Willemze, R. ;Peters, W. G. ;Hennik, M. B. ;Fibbe, W. E. ;Kootte, A. M. M. ;Berk 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) ⚖ 314 KB